Author + information
- Received May 16, 2008
- Revision received July 10, 2008
- Accepted July 21, 2008
- Published online November 1, 2008.
- Uri Elkayam, MD, FACC⁎ (, )
- Mohamed W. Akhter, MD,
- Ming Liu, MD,
- Parta Hatamizadeh, MD and
- Mohamad N. Barakat, MD
Reprint requests and correspondence:
Dr. Uri Elkayam, LAC/USC Medical Center, 1200 North State Street, Los Angeles, California 90033
Objectives We evaluated the magnitude and site of action of the nesiritide mediated renal vasodilatory effect in patients with heart failure (HF).
Background Nesiritide, a recombinant human B-type natriuretic peptide is approved for the treatment of acute decompensated HF and has been shown to exert favorable hemodynamic, neurohormonal, and symptomatic effects. The renal effect of nesiritide in HF patients has not been well defined.
Methods In 15 patients with acute decompensated HF, intravascular Doppler and quantitative angiography of the renal artery were used to assess the effect of nesiritide on renal artery diameter and velocity time integral as well as renal blood flow and vascular resistance. Nesiritide was administered intravenously at a standard dose of 2 μg/kg bolus followed by a continuous infusion at a rate of 0.01 μg/kg/min. Assessment of nesiritide effect was made at 15 min.
Results Nesiritide infusion was associated with a significant central hemodynamic effect including a fall in mean pulmonary artery pressure (36 ± 12 mm Hg to 31 ± 13 mm Hg, p < 0.001), mean pulmonary capillary wedge pressure (21 ± 2 mm Hg to 15 ± 10 mm Hg, p < 0.001), and systemic vascular resistance (1,995 ± 532 dynes·s·cm−5 to 1,563 ± 504 dynes·s·cm−5, r < 0.001), and an increase in cardiac output from 3.9 ± 1.2 l/min to 4.6 ± 1.6 l/min (p = 0.001). Nesiritide was also associated with a significant vasodilatory effect on the large conductance renal arteries resulting in an increase in renal artery diameter from 6.2 ± 0.7 mm to 6.7 ± 0.8 mm (p < 0.001). At the same time, there was a concomitant fall in mean renal artery pressure (99 ± 17 mm Hg to 89 ± 13 mm Hg, p = 0.002) and renal blood flow velocity time integral (27 ± 15 cm/beat to 23 ± 15 cm/beat, p = 0.008) and, therefore, no significant change in renal blood flow or renal vascular resistance.
Conclusions The nesiritide effect on the renal circulation in patients with HF is complex, with a marked vasodilatory action on the large, conductance renal arteries but a concomitant fall in velocity time integral and no effect on renal vascular resistance or renal blood flow. Lack of increase in renal blood flow may be due to a fall in renal blood pressure or an intrarenal vasoconstrictive effect.
The study was supported by a research grant from SCIOS (Fremont, California). Dr. Elkayam has served as a consultant and speaker for SCIOS.
- Received May 16, 2008.
- Revision received July 10, 2008.
- Accepted July 21, 2008.
- American College of Cardiology Foundation